Manufacturer profile
AstraZeneca Pharmaceuticals LP
Pharmaceutical company9 products tracked
9
products tracked
176,289
total reports
4
recalls on record
70.6%
serious overall
Products
showing 9 of 9
| Product | Approved | Reports ↓ | Top signal | Recalls |
|---|---|---|---|---|
| 2005 | 52,309 | Early satiety | 0 | |
| 2015 | 30,472 | Acquired gene mutation | 0 | |
| 2014 | 20,092 | Ovarian cancer recurrent | 1 | |
| 2017 | 18,784 | Asthma | 1 | |
| 2017 | 18,758 | Radiation pneumonitis | 1 | |
| 2017 | 11,444 | Lymphadenopathy | 0 | |
| — | 11,180 | Device use issue | 1 | |
| — | 9,320 | Device use issue | 0 | |
| 2022 | 3,930 | Liver carcinoma ruptured | 0 |
Recall history · 5 on record
| Date | Class | Reason | Firm |
|---|---|---|---|
| Oct 8, 2025 | II | Lack of Assurance of Sterility: | ASTRAZENECA PHARMACEUTICALS |
| Jun 12, 2019 | II | Lack of Assurance of Sterility | Infusion Options, Inc. |
| Feb 23, 2018 | III | Failed Impurities/Degradation Specifications; elevated levels of quality attribute Form L (polymorph). | AstraZeneca Pharmaceuticals LP |
| Jun 10, 2015 | II | Presence of Foreign Tablets/Capsules: Confimed customer compliant by a retail pharmacist that an unopened bottle labeled as NEXIUM¿ capsules contained 60 SEROQUEL¿ XR tablets. | AstraZeneca Pharmaceuticals LP |
| Jun 21, 2013 | II | Presence of Precipitate; potential for incomplete constitution upon addition of diluent. | AstraZeneca Pharmaceuticals LP |
Class I = reasonable probability of serious harm · Class II = temporary or reversible · Class III = unlikely to cause harm.
Registration status
Some products from AstraZeneca Pharmaceuticals LP are not FDA-registered for human use. For unregistered substances (peptides, SARMs without human registration), no legitimate human-use supplier exists. The absence of a sourcing route is the safety information.